Publications by authors named "I Rudolph"
Background: Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation clearance after transplantation is unclear.
Methods: We used highly sensitive polymerase-chain-reaction technology to analyze the dynamics of driver mutations in peripheral-blood samples from 324 patients with myelofibrosis (73% with mutations, 23% with mutations, and 4% with mutations) who were undergoing transplantation after reduced-intensity conditioning.
Despite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications. Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear. Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group).
View Article and Find Full Text PDFBackground: Pulmonary vein isolation (PVI) using pulsed field ablation (PFA) or cryoballoon ablation (CBA) are commonly used single-shot techniques for the treatment of patients with atrial fibrillation (AF). The number of overweight (BMI 25-30 kg/m) and obese (BMI>30 kg/m) patients undergoing PVI is increasing, but data on this patient population is limited.
Methods: Consecutive AF patients with a BMI ≥25 kg/m undergoing PFA- or CBA-PVI were included in this retrospective analysis.
Article Synopsis
- The optimal TBI dose for patients with high-risk acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (SCT) is still uncertain.
- A retrospective analysis compared outcomes of patients treated with 8 Gy and 12 Gy total body irradiation (TBI) along with fludarabine and PTCy, revealing that while both doses show similar overall and leukemia-free survival, the 12 Gy dose offers better outcomes for MRD-positive patients.
- The study suggests that the 8 Gy TBI results in lower non-relapse mortality but a higher relapse rate compared to 12 Gy, highlighting the need for further research to confirm these results with larger MRD patient groups.
Aims: Pulmonary vein isolation (PVI) represents the gold standard in the treatment of atrial fibrillation (AF) and the use of single-shot techniques, such as cryoballoon ablation (CBA) and pulsed field ablation (PFA) using a pentaspline catheter, has gained prominence. Recent studies hypothesize that PFA might be superior to CBA, although procedural efficacy and safety data are inconsistent. A meta-analysis was conducted to compare both energy sources for the treatment of AF.
View Article and Find Full Text PDF